Table 2.
Neurologists’ perceptions of patient satisfaction and adherence with treatment: comparison with fingolimod
| Fingolimod
|
IM IFN β-1a
|
IFN β-1b (Betaseron® /Extavia®) |
Glatiramer acetate
|
SC IFN β-1a
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | P-value | N (%) | P-value | N (%) | P-value | |||
| N (%) | P-value | ||||||||
| Patient satisfaction, Na | 87 | 99 | 92 | 101 | 96 | ||||
| Dissatisfied | 5 (5.7%) | 6 (6.1%) | 0.0006 | 3 (3.3%) | 0.0007 | 5 (5.0%) | 0.017 | 3 (3.1%) | 0.0020 |
| Satisfied | 55 (63.2%) | 85 (85.9%) | 83 (90.2%) | 82 (81.2%) | 85 (88.5%) | ||||
| Very/extremely satisfied | 27 (31.0%) | 8 (8.1%) | 6 (6.5%) | 14 (13.9%) | 8 (8.3%) | ||||
| Patient adherence, Na,b | 84 | 98 | 88 | 100 | 94 | ||||
| All/most | 79 (94.0%) | 91 (92.9%) | 0.75 | 66 (75.0%) | 0.0006 | 78 (78.0%) | 0.0022 | 79 (84.0%) | 0.035 |
| Some/few | 5 (6.0%) | 7 (7.1%) | 22 (25.0%) | 22 (22.0%) | 15 (16.0%) | ||||
Notes:
a
The number of neurologists prescribing the medication;
b
excludes neurologists reporting “I don’t know.” Betaseron®; Bayer AG, Leverkusen, Germany. Extavia®; Novartis AG, Basel, Switzerland.
Abbreviations: N, number; IM, intramuscular; IFN, interferon; SC, subcutaneous.